A Multiple Dose Safety And Pharmacokinetic (PK) Study Of PF-06427878 In Overweight-Obese, Otherwise Healthy Subjects
Status:
Completed
Trial end date:
2017-04-12
Target enrollment:
Participant gender:
Summary
PF-06427878 is a new compound proposed for the treatment of hyperlipidemia. The primary
purpose of this study is to evaluate the safety, tolerability, and pharmacokinetics after 2
weeks of dosing of PF-06427878 in overweight-obese, otherwise healthy adult subjects.